The latest price target for Tenax Therapeutics (NASDAQ:TENX) was reported by Guggenheim on December 17, 2025. The analyst firm set a price target for $25.00 expecting TENX to rise to within 12 months (a possible 88.14% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Tenax Therapeutics (NASDAQ:TENX) was provided by Guggenheim, and Tenax Therapeutics maintained their buy rating.

There is no last upgrade for Tenax Therapeutics

There is no last downgrade for Tenax Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tenax Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tenax Therapeutics was filed on December 17, 2025 so you should expect the next rating to be made available sometime around December 17, 2026.

While ratings are subjective and will change, the latest Tenax Therapeutics (TENX) rating was a maintained with a price target of $14.00 to $25.00. The current price Tenax Therapeutics (TENX) is trading at is $13.29, which is out of the analyst’s predicted range.